Feedback
What do they think of us?
We promote research by offering comprehensive support in the management and implementation of clinical studies.
We provide advice, solutions and structures that accompany the investigator throughout the clinical study process, from design to execution, guaranteeing compliance with all ethical and regulatory standards and ensuring the quality and validity of the research.
Our success lies in the combined efforts from the CRO and CTU teams that provide thorough support to the research team.
What do they think of us?
Check out some of the latest projects we’ve worked on.
A research team led by Fundació Lluita contra les Infeccions and IrsiCaixa, in collaboration with Hospital Universitari Germans Trias i Pujol and the BBRC, is investigating the impact of lamivudine (3TC) on biomarkers associated with mild cognitive impairment (MCI). The study will include 25 participants and will analyze the drug’s effects on type I interferon-stimulated genes.
To ensure the project’s success, ScienHub Research Support provides full assistance through its CRO and CTU, ensuring protocol compliance and good clinical practices. Additionally, the study will serve to evaluate
The Fundació Lluita contra les Infeccions and PharmaMar launched the Thalassa 2.0 trial, a phase II study aimed at evaluating the effectiveness of plitidepsin in treating long COVID. The study seeks to provide new therapeutic options for patients.
ScienHub Research Support is in charge of the study’s planning, execution and monitoring reinforcing its commitment to innovative treatments. Its intense involvement highlights its key role and commitment in advancing potential therapies for long COVID and strengthening its presence in supporting medical research.
The BCN03 clinical trial, a phase I study led by IrsiCaixa, is a randomized, double-blind, placebo-controlled study involving 30 participants. It aims to evaluate the safety, tolerability, and immunogenicity of therapeutic vaccines against HIV-1 (ChAdOx1.HTI, MVA.HTI, and ConM SOSIP.v7 gp140) to develop immune-based strategies for controlling the virus without lifelong treatment.
The ScienHub Research Support team (CTU/CRO) managed the trial’s procedures, regulatory processes, and study monitoring, providing full support to the research team throughout all phases—from initiation to completion.